Cell Signaling Technology, Inc.

Bluefin Biomedicine, Inc.

Klarisa Rikova

Ailan Guo

Anthony Paul Possemato

Ting-Lei Gu

Jian Yu

Herbert Haack

Laura Sullivan

Joan MacNeill

Nels Eric Pederson

Scott Michael Lonning

Aleksandr Tkachev

Tinglei Gu

Kimberly A Lee

Jason G Beaudet

Hong Ren

Roberto Polakiewicz

Albrecht Moritz

Katherine Eleanor Crosby

Yu Li

Jaime Rene Darce

Isabel Milan Chu

Qingfu Zeng

Charles Farnsworth

Peter Hornbeck

John Rush

Valerie Goss

Sean Andre Beausoleil

Jeffrey Joseph Mitchell

Sean A Beausoleil

Robert Polakiewicz

Matthew Stokes

Erik Spek

Jessica Cherry

Corinne Michaud

Kevin Jefferies

Joan Macneil

Disclosed herein are anti-lymphocyte antigen 6 complex, locus H (LY6H) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Anti-LY6H antibodies and antibody drug conjugates

This disclosure relates to anti-cancer antibodies and methods of treatment, detection, and diagnosis using the same.

Anti-CUB domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof

Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof

Disclosed herein are anti-immunoglobulin-like transcript-3 (ILT3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Anti-ILT3 antibodies and antibody drug conjugates

Disclosed herein are transmembrane protein with EGF-like and two-follistatin-like domains 1 (TMEFF1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Anti-TMEFF1 antibodies and antibody drug conjugates

Disclosed herein are anti-Seizure Related 6 Homolog Like 2 (SEZ6L2) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Anti-SEZ6L2 antibodies and antibody drug conjugates

Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have been identified herein in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.

Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer

Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The invention also provides methods for determining the presence of these mutant polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.

Compositions for detecting mutant anaplastic lymphoma kinase in human lung cancer

Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have been identified herein in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFC). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.

Methods of treating non-small cell lung carcinoma (NSCLC)

Growing community of inventors

Reading, MA, United States of America

Klarisa Rikova